Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses
Background Omalizumab is an established anti-IgE therapy for the treatment of allergic
diseases that prevents IgE from binding to its receptor. QGE031 is an investigational anti-IgE
antibody that binds IgE with higher affinity than omalizumab. Objective This study compared
the effects of QGE031 with those of omalizumab on clinical efficacy, IgE levels, and FcεRI
expression in a clinical model of allergic asthma. Methods Thirty-seven patients with mild
allergic asthma were randomized to subcutaneous omalizumab, placebo, or QGE031 at 24 …
diseases that prevents IgE from binding to its receptor. QGE031 is an investigational anti-IgE
antibody that binds IgE with higher affinity than omalizumab. Objective This study compared
the effects of QGE031 with those of omalizumab on clinical efficacy, IgE levels, and FcεRI
expression in a clinical model of allergic asthma. Methods Thirty-seven patients with mild
allergic asthma were randomized to subcutaneous omalizumab, placebo, or QGE031 at 24 …